NCT06441747 2026-05-06Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)Australasian Gastro-Intestinal Trials GroupPhase 2 Recruiting40 enrolled